MedTrace Logo

Evaluation of Benztropine for Cocaine Craving - 2

NCT00000333 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-02-24

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.

Conditions

  • Cocaine-Related Disorders

Interventions

DRUG

Benztropine

Sponsors & Collaborators

  • Washington D.C. Veterans Affairs Medical Center

    collaborator FED

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Steven Deutsch, M.D. · Washington D.C. Veterans Affairs Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
22 Years
Max Age
48 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2003-01-31
Completion
2003-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000333 on ClinicalTrials.gov